Table 3.
Certainty Assessment | |||||||||
---|---|---|---|---|---|---|---|---|---|
Outcome | Pooled Incidence (95% CI) | No. of Cohort Studies | Type of Evidence | Quality | Consistency | Directness | Effect Size | Overall Quality | Certainty |
Radiographic response | 80% (58%-96%) | 6 | +2 | –1 | –1 | 0 | +1 | +1 | Very low |
Clinical response | 57% (43%-71%) | 4 | +2 | –2 | +1 | –1 | +2 | +2 | Low |
Serious adverse event | 8% (2%-17%) | 7 | +2 | –1 | +1 | 0 | +1 | +3 | Moderate |
Progression | 51% (28%-74%) | 6 | +2 | –2 | –1 | 0 | +2 | +1 | Very low |
Abbreviation: GRADE, Grading of Recommendations, Assessment, Development and Evaluations.
Overall quality score is determined based on the sum of included domains. Type of evidence is based on design of included studies (range, +2 to +4). Study quality reflects blinding and allocation, follow-up and withdrawals, sparsity of data, and methodological concerns (range, –3 to 0). Consistency is graded based on heterogeneity of included population and study end points with respect to one another (range, –1 to +1). Directness is graded based on generalizability of included results (range, –2 to 0). Effect size is graded based on the overlap of 95% CI estimates within 10% of either 0% or 100% incidence (range, 0 to 2). The overall quality of results for each outcome can be considered high (≥ 4 points), moderate (3 points), low (2 points), or very low (≤ 1 point).